PT2630146T - Sal tosilato de (8s,9r)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-di-hidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona cristalino - Google Patents
Sal tosilato de (8s,9r)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-di-hidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona cristalinoInfo
- Publication number
- PT2630146T PT2630146T PT117770057T PT11777005T PT2630146T PT 2630146 T PT2630146 T PT 2630146T PT 117770057 T PT117770057 T PT 117770057T PT 11777005 T PT11777005 T PT 11777005T PT 2630146 T PT2630146 T PT 2630146T
- Authority
- PT
- Portugal
- Prior art keywords
- phtalazin
- crystaline
- pyrido
- triazol
- fluorophenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40547610P | 2010-10-21 | 2010-10-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2630146T true PT2630146T (pt) | 2020-07-20 |
Family
ID=44903424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT117770057T PT2630146T (pt) | 2010-10-21 | 2011-10-20 | Sal tosilato de (8s,9r)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-di-hidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona cristalino |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US8735392B2 (enExample) |
| EP (2) | EP2630146B1 (enExample) |
| JP (6) | JP2013540158A (enExample) |
| KR (4) | KR20190120458A (enExample) |
| CN (1) | CN103282365B (enExample) |
| AR (1) | AR083502A1 (enExample) |
| AU (2) | AU2011317040B2 (enExample) |
| BR (1) | BR112013009117A2 (enExample) |
| CA (1) | CA2814581C (enExample) |
| CY (1) | CY1123356T1 (enExample) |
| DK (1) | DK2630146T3 (enExample) |
| ES (1) | ES2816600T3 (enExample) |
| HU (1) | HUE051535T2 (enExample) |
| IL (2) | IL225789B (enExample) |
| MX (1) | MX362563B (enExample) |
| NZ (1) | NZ609490A (enExample) |
| PL (1) | PL2630146T3 (enExample) |
| PT (1) | PT2630146T (enExample) |
| RU (1) | RU2598606C3 (enExample) |
| SG (2) | SG10201710578TA (enExample) |
| SI (1) | SI2630146T1 (enExample) |
| TW (2) | TWI557123B (enExample) |
| WO (1) | WO2012054698A1 (enExample) |
| ZA (1) | ZA201302810B (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2326650B9 (en) | 2008-08-06 | 2014-09-10 | BioMarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
| EP2406389B1 (en) | 2009-03-13 | 2019-05-08 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| CA2944788C (en) | 2009-06-29 | 2023-08-22 | Agios Pharmaceuticals, Inc. | Compounds, and compositions thereof, which modulate pyruvate kinase m2, and methods of making same |
| CA2793835C (en) | 2009-10-21 | 2021-07-20 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| AU2011212928B2 (en) | 2010-02-03 | 2016-06-23 | Medivation Technologies Llc | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose) polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency |
| MX340319B (es) * | 2010-02-08 | 2016-07-06 | Medivation Technologies Inc | Procesos para sintetizar derivados de dihidropiridoftalazinona. |
| ES2816600T3 (es) | 2010-10-21 | 2021-04-05 | Medivation Tech Llc | Sal tosilato de (8S,9R)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1H-1,2,4-triazol-5-il)-8,9-dihidro-2H-pirido[4,3,2-de]ftalazin-3(7H)-ona cristalina |
| KR101873543B1 (ko) | 2011-05-03 | 2018-07-02 | 아지오스 파마슈티컬스 아이엔씨. | 치료에 사용하기 위한 피루베이트 키나아제 활성제 |
| CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN103857661B (zh) * | 2011-08-11 | 2016-11-16 | 拜耳知识产权有限责任公司 | 1,2,4‑三唑基取代的酮烯醇 |
| WO2013028495A1 (en) * | 2011-08-19 | 2013-02-28 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma |
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| HK1213798A1 (zh) | 2012-10-15 | 2016-07-15 | 安吉奥斯医药品有限公司 | 治療性化合物和組合物 |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| CA2917671A1 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | 2,4-or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer |
| WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| DK3105226T3 (da) | 2014-02-13 | 2019-10-14 | Incyte Corp | Cyclopropylaminer som lsd1-inhibitorer |
| PT3105218T (pt) | 2014-02-13 | 2019-12-05 | Incyte Corp | Ciclopropilaminas como inibidores de lsd1 |
| RS62178B1 (sr) * | 2014-03-14 | 2021-08-31 | Les Laboratoires Servier Sas | Farmaceutske kompozicije terapeutski aktivnih jedinjenja |
| CA2942072C (en) | 2014-03-14 | 2022-07-26 | Agios Pharmaceuticals, Inc. | Pharmaceutical compositions and use of (s)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-( 4-cyanopyridin-2-yl)-n-( 5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| EA201790290A1 (ru) * | 2014-07-31 | 2017-07-31 | Медивэйшн Текнолоджиз, Инк. | Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения |
| EP3626720A1 (en) | 2015-04-03 | 2020-03-25 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| DK3307271T3 (da) | 2015-06-11 | 2023-10-09 | Agios Pharmaceuticals Inc | Fremgangsmåder til anvendelse af pyruvatkinase-aktivatorer |
| KR102710120B1 (ko) | 2015-08-12 | 2024-09-27 | 인사이트 홀딩스 코포레이션 | Lsd1 저해제의 염 |
| DK3362066T3 (da) | 2015-10-15 | 2021-11-22 | Les Laboratoires Servier Sas | Kombinationsterapi til behandling af maligniteter |
| MA71411A (fr) | 2015-10-15 | 2025-04-30 | Les Laboratoires Servier | Polythérapie pour le traitement de tumeurs malignes |
| CA3003422A1 (en) * | 2015-10-26 | 2017-05-04 | Medivation Technologies Llc | Treatment of small cell lung cancer with a parp inhibitor |
| US10246461B2 (en) | 2016-02-29 | 2019-04-02 | Genentech, Inc. | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase |
| CA3078806A1 (en) | 2017-10-13 | 2019-04-18 | Merck Patent Gmbh | Combination of a parp inhibitor and a pd-1 axis binding antagonist |
| TW201938165A (zh) | 2017-12-18 | 2019-10-01 | 美商輝瑞股份有限公司 | 治療癌症的方法及組合療法 |
| WO2019235822A1 (ko) | 2018-06-04 | 2019-12-12 | 엘지전자 주식회사 | 어파인 움직임 예측을 이용하여 비디오 신호를 처리하는 방법 및 장치 |
| US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| US10942500B2 (en) * | 2018-06-11 | 2021-03-09 | Purdue Research Foundation | System architecture and method of processing data therein |
| US10284866B1 (en) * | 2018-07-02 | 2019-05-07 | Tencent America LLC | Method and apparatus for video coding |
| CN112424671B (zh) | 2018-07-13 | 2023-10-27 | 奇跃公司 | 用于显示双目变形补偿的系统和方法 |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| US20210355223A1 (en) | 2018-11-05 | 2021-11-18 | Pfizer Inc. | Combinations for Treating Cancer |
| JP7713934B2 (ja) * | 2019-10-10 | 2025-07-28 | スミトモ ファーマ スウィッツァーランド ゲーエムベーハー | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶溶媒和形 |
| CA3174908A1 (en) | 2020-03-09 | 2021-09-16 | Pfizer Inc. | Fusion proteins and uses thereof |
| KR20230107647A (ko) | 2020-11-13 | 2023-07-17 | 화이자 인코포레이티드 | 탈라조파립 연질 젤라틴 캡슐 투여 형태 |
| CA3203814A1 (en) | 2020-12-07 | 2022-06-16 | Pfizer Inc. | Methods of identifying a tumor that is sensitive to treatment with talazoparib and methods of treatment thereof |
| BR112023018906A2 (pt) | 2021-03-24 | 2023-10-10 | Astellas Pharma Inc | Combinação de talazoparib e um antiandrógeno para o tratamento de câncer de próstata metastático sensível à castração com mutação no gene ddr |
| WO2023131894A1 (en) | 2022-01-08 | 2023-07-13 | Pfizer Inc. | Genomic loss of heterozygosity as a predictive biomarker for treatment with talazoparib and methods of treatment thereof |
| WO2023201338A1 (en) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
| EP4532493A1 (en) | 2022-06-01 | 2025-04-09 | Ideaya Biosciences, Inc. | Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof |
| TWI883565B (zh) | 2022-10-02 | 2025-05-11 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| TW202425976A (zh) | 2022-12-17 | 2024-07-01 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| WO2025210510A1 (en) | 2024-04-04 | 2025-10-09 | Pfizer Inc. | Tmprss2-erg and rb1 as predictive biomarkers for treatment with a parp inhibitor |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4415504A (en) | 1981-09-21 | 1983-11-15 | Tanabe Seiyaku Co., Ltd. | p-Hydroxyphenylglycine.α-phenylethanesulfonate, process for production thereof and utilization thereof in resolution of p-hydroxyphenylglycine |
| JPS58225065A (ja) | 1982-06-21 | 1983-12-27 | Nippon Shinyaku Co Ltd | ２−キノロン誘導体 |
| US5328905A (en) | 1987-07-20 | 1994-07-12 | Duphar International Research B.V. | 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives |
| GB9505538D0 (en) | 1995-03-18 | 1995-05-03 | Ciba Geigy Ag | New compounds |
| ID19155A (id) | 1996-12-13 | 1998-06-18 | Tanabe Seiyaku Co | Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya |
| DE19727410A1 (de) | 1997-06-27 | 1999-01-07 | Hoechst Schering Agrevo Gmbh | 3-(5-Tetrazolylcarbonyl)-2-chinolone und diese enthaltende nutzpflanzenschützende Mittel |
| US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| TW430656B (en) | 1997-12-03 | 2001-04-21 | Dainippon Ink & Chemicals | Quinolinone derivative, method for preparing the same, and anti-allergic agent |
| WO1999059975A1 (en) | 1998-05-15 | 1999-11-25 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds which inhibit parp activity |
| DE19921567A1 (de) | 1999-05-11 | 2000-11-16 | Basf Ag | Verwendung von Phthalazine-Derivaten |
| JP2001302669A (ja) | 2000-04-18 | 2001-10-31 | Meiji Seika Kaisha Ltd | 三環性フタラジノン誘導体 |
| JP2002284699A (ja) | 2001-03-28 | 2002-10-03 | Sumitomo Pharmaceut Co Ltd | 視細胞変性疾患治療剤 |
| AR036081A1 (es) | 2001-06-07 | 2004-08-11 | Smithkline Beecham Corp | Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos |
| SE0102315D0 (sv) | 2001-06-28 | 2001-06-28 | Astrazeneca Ab | Compounds |
| IL163562A0 (en) * | 2002-02-19 | 2005-12-18 | Ono Pharmaceutical Co | fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient |
| EP1340819A1 (en) | 2002-02-28 | 2003-09-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Microsatellite markers |
| GB0221443D0 (en) | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
| EP1400244A1 (en) | 2002-09-17 | 2004-03-24 | Warner-Lambert Company LLC | New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors |
| CA2505876A1 (en) | 2002-11-12 | 2004-05-27 | Mochida Pharmaceutical Co., Ltd. | Novel parp inhibitors |
| MXPA05009661A (es) * | 2003-03-12 | 2006-03-08 | Kudos Pharm Ltd | Derivados de ftalazinona. |
| JP4824566B2 (ja) | 2003-05-28 | 2011-11-30 | エーザイ インコーポレーテッド | Ｐａｒｐを阻害するための化合物、方法、および医薬組成物 |
| JP5084269B2 (ja) | 2004-02-18 | 2012-11-28 | アストラゼネカ アクチボラグ | テトラゾール化合物及び代謝共役型グルタミン酸受容体アンタゴニストとしてのそれらの使用 |
| GB0612971D0 (en) | 2006-06-30 | 2006-08-09 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| KR20100007956A (ko) | 2007-05-03 | 2010-01-22 | 화이자 리미티드 | 나트륨 채널 조절제로서의 2-피리딘 카복스아마이드 유도체 |
| WO2009024190A1 (en) | 2007-08-22 | 2009-02-26 | 4Sc Ag | Indolopyridines as inhibitors of the kinesin spindle protein (eg5 ) |
| JP2011511078A (ja) | 2008-02-06 | 2011-04-07 | レアド トヘラペウトイクス，インコーポレーテッド | ポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）のベンズオキサゾールカルボキサミド阻害剤 |
| EP2326650B9 (en) | 2008-08-06 | 2014-09-10 | BioMarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
| MX2011001563A (es) | 2008-08-12 | 2011-03-04 | Boehringer Ingelheim Int | Procedimiento para la preparacion de compuestos de piperazina sustituidos con cloalquilo. |
| AU2011212928B2 (en) | 2010-02-03 | 2016-06-23 | Medivation Technologies Llc | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose) polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency |
| US20110190266A1 (en) | 2010-02-04 | 2011-08-04 | Daniel Chu | 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) |
| MX340319B (es) | 2010-02-08 | 2016-07-06 | Medivation Technologies Inc | Procesos para sintetizar derivados de dihidropiridoftalazinona. |
| WO2011130661A1 (en) | 2010-04-16 | 2011-10-20 | Biomarin Pharmaceutical Inc. | Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp) |
| WO2011140009A1 (en) | 2010-05-04 | 2011-11-10 | Biomarin Pharmaceutical Inc. | Methods of using semi-synthetic glycopeptides as antibacterial agents |
| ES2816600T3 (es) | 2010-10-21 | 2021-04-05 | Medivation Tech Llc | Sal tosilato de (8S,9R)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1H-1,2,4-triazol-5-il)-8,9-dihidro-2H-pirido[4,3,2-de]ftalazin-3(7H)-ona cristalina |
| WO2012166151A1 (en) | 2011-06-03 | 2012-12-06 | Biomarin Pharmaceutical Inc. | Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml) |
| WO2013028495A1 (en) | 2011-08-19 | 2013-02-28 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma |
| US20130053365A1 (en) | 2011-08-30 | 2013-02-28 | Biomarin Pharmaceutical, Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
| US20160280691A1 (en) | 2013-11-07 | 2016-09-29 | Biomarin Pharmaceutical Inc. | Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes |
| EA201790290A1 (ru) | 2014-07-31 | 2017-07-31 | Медивэйшн Текнолоджиз, Инк. | Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения |
-
2011
- 2011-10-20 ES ES11777005T patent/ES2816600T3/es active Active
- 2011-10-20 KR KR1020197030773A patent/KR20190120458A/ko not_active Ceased
- 2011-10-20 PT PT117770057T patent/PT2630146T/pt unknown
- 2011-10-20 KR KR1020187016905A patent/KR20180069132A/ko not_active Ceased
- 2011-10-20 RU RU2013123036A patent/RU2598606C3/ru active Protection Beyond IP Right Term
- 2011-10-20 WO PCT/US2011/057039 patent/WO2012054698A1/en not_active Ceased
- 2011-10-20 CA CA2814581A patent/CA2814581C/en active Active
- 2011-10-20 SG SG10201710578TA patent/SG10201710578TA/en unknown
- 2011-10-20 EP EP11777005.7A patent/EP2630146B1/en active Active
- 2011-10-20 JP JP2013535079A patent/JP2013540158A/ja active Pending
- 2011-10-20 SG SG2013029731A patent/SG189939A1/en unknown
- 2011-10-20 AU AU2011317040A patent/AU2011317040B2/en active Active
- 2011-10-20 US US13/277,607 patent/US8735392B2/en active Active
- 2011-10-20 BR BR112013009117A patent/BR112013009117A2/pt not_active Application Discontinuation
- 2011-10-20 TW TW100138150A patent/TWI557123B/zh active
- 2011-10-20 HU HUE11777005A patent/HUE051535T2/hu unknown
- 2011-10-20 MX MX2013004195A patent/MX362563B/es active IP Right Grant
- 2011-10-20 EP EP20175014.8A patent/EP3757106A1/en not_active Withdrawn
- 2011-10-20 CN CN201180062085.0A patent/CN103282365B/zh active Active
- 2011-10-20 AR ARP110103892A patent/AR083502A1/es not_active Application Discontinuation
- 2011-10-20 DK DK11777005.7T patent/DK2630146T3/da active
- 2011-10-20 KR KR1020217006784A patent/KR20210028747A/ko not_active Ceased
- 2011-10-20 KR KR1020137012297A patent/KR20140009181A/ko not_active Ceased
- 2011-10-20 PL PL11777005T patent/PL2630146T3/pl unknown
- 2011-10-20 NZ NZ609490A patent/NZ609490A/en unknown
- 2011-10-20 SI SI201131903T patent/SI2630146T1/sl unknown
- 2011-10-20 TW TW105123467A patent/TWI643858B/zh active
-
2013
- 2013-04-17 IL IL225789A patent/IL225789B/en active IP Right Grant
- 2013-04-18 ZA ZA2013/02810A patent/ZA201302810B/en unknown
-
2014
- 2014-04-14 US US14/252,668 patent/US20140228369A1/en not_active Abandoned
-
2016
- 2016-11-18 JP JP2016224670A patent/JP2017061526A/ja active Pending
-
2017
- 2017-03-07 AU AU2017201564A patent/AU2017201564B2/en active Active
- 2017-07-17 US US15/651,735 patent/US10189837B2/en active Active
-
2018
- 2018-10-11 JP JP2018192521A patent/JP2019034951A/ja not_active Withdrawn
-
2019
- 2019-12-17 IL IL271497A patent/IL271497A/en unknown
-
2020
- 2020-07-09 JP JP2020118281A patent/JP2020169209A/ja not_active Withdrawn
- 2020-09-22 CY CY20201100893T patent/CY1123356T1/el unknown
-
2022
- 2022-08-02 JP JP2022123448A patent/JP2022140637A/ja not_active Withdrawn
-
2024
- 2024-08-07 JP JP2024130494A patent/JP2024150772A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271497A (en) | Tosylate salt of (S8, R9)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-H1- 4,2,1-triazol-5-yl)-9,8-dihydro-H2 -Crystalline pyrido[2,3,4-de]phthalazine-3(H3)-one | |
| EP2656847A4 (en) | CONJUGATE FOR PHOTODYNAMIC DIAGNOSIS OR THERAPY AND PREPARATION METHOD THEREOF | |
| ZA201209632B (en) | Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof | |
| PL2477648T3 (pl) | Synergistyczna terapia anty-cd47 dla nowotworów hematologicznych | |
| ZA201300100B (en) | Indolizine derivatives,process for the preparation thereof and therapeutic use thereof | |
| EP2619203A4 (en) | TRICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND APPLICATIONS THEREOF | |
| PL2616065T3 (pl) | GLIKO-PODSTAWIONE DIHYDROKSYCHLORYNY I ß-FUNKCJONALIZOWANE CHLORYNY DO PRZECIWDROBNOUSTROJOWEJ TERAPII FOTODYNAMICZNEJ | |
| EP2552833A4 (en) | Surface-modified zeolites and methods for preparing the same | |
| IL229993A (en) | 8 - Alkoxy [1,2,4] triazolo [5,1 – c] pyrimidine– 2 | |
| IL221479A0 (en) | Triazolo [4,5-b] pyridin derivatives | |
| EP2624834A4 (en) | LACTONE-BASED MACROCYCLIC COMPOUNDS AND METHODS OF USE | |
| IL220448A (en) | Pyridine [3,2 - d] Pyrimidine - 7 (8h) - Their medical uses and uses | |
| ZA201304074B (en) | Pyrazino[2,3-d]isoxazole derivative | |
| HK1188783B (en) | Crystaline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phtalazin-3(7h)-one tosylate salt | |
| IL236808B (en) | Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one | |
| ZA201303580B (en) | Oxazolo [5,4-b]pyridin-5-yl compounds and their use for the treatment of cancer | |
| SI2477990T1 (sl) | 5-fenil-pirazolopiridinski derivati, njihova priprava in terapevtska uporaba | |
| EP2651937B8 (en) | Imidazo[4,5-c]quinolin-1-yl derivative useful in therapy | |
| HK1188783A (zh) | 結晶的(8s，9r)-5-氟-8-(4-氟苯基)-9-(1-甲基-1h-1，2，4-三唑-5-基)-8，9-二氫-2h-吡啶並[4，3，2-de]酞嗪-3(7h)-酮甲苯磺酸鹽 | |
| IL226388A0 (en) | New indolizine derivatives, their preparation and medical use | |
| HK1179251A (en) | Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof | |
| HK1186470A (en) | Oxazolo [5, 4 -b]pyridin- 5 -yl compounds and their use for the treatment of cancer | |
| AU2010902149A0 (en) | Safe drink detector | |
| IL225237A0 (en) | A permanent vehicle blocking system made of refillable gauze | |
| HK1179250A (en) | Indolizine derivatives, process for the preparation thereof and therapeutic use thereof |